ExoLytics

Executive Summary

ExoLytics is an early-stage biotechnology company pioneering the use of engineered endolysins—enzymes derived from bacteriophages—to develop precision antimicrobial therapies against drug-resistant infections. Founded in 2018 and headquartered in San Diego, the company aims to address the urgent global health crisis of antimicrobial resistance (AMR) by leveraging a novel mechanism of action that specifically targets bacterial cell walls without disrupting the microbiome. Unlike traditional small-molecule antibiotics, endolysins offer rapid, species-specific killing and a low propensity for resistance development. ExoLytics' platform enables the engineering of endolysins with optimized stability, potency, and manufacturing scalability. The company is currently in preclinical development, focusing on high-priority pathogens such as MRSA and Pseudomonas aeruginosa. With no disclosed funding or partnership history, ExoLytics represents a high-risk but potentially high-reward opportunity in the anti-infective space. Successful advancement through preclinical studies and into the clinic could position the company as a key player in next-generation antibiotics, though substantial capital and clinical validation are required. The near-term outlook depends on securing financing and generating compelling efficacy data in animal models.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Animal Models60% success
• Q3 2026Series A Financing Round50% success
• Q2 2026Research Collaboration or Licensing Deal40% success